Assessing the Clinical Impact of Prostate-Specific Antigen Assay Variability and Nonequimolarity: A Simulation Study Based on the Population of the United Kingdom | Zendy

Andrew Roddam | Zendy; Christopher P. Price | Zendy; Naomi E. Allen | Zendy; Anthony Milford Ward | Zendy

Open Access

Assessing the Clinical Impact of Prostate-Specific Antigen Assay Variability and Nonequimolarity: A Simulation Study Based on the Population of the United Kingdom

Author(s) -

Andrew Roddam,

Christopher P. Price,

Naomi E. Allen,

Anthony Milford Ward

Publication year - 2004

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2004.031138

Subject(s) - false positive paradox , prostate specific antigen , prostate biopsy , medicine , biopsy , false positive rate , prostate , statistics , population , false negative reactions , false positives and false negatives , prostate cancer , mathematics , cancer , environmental health

Prostate-specific antigen (PSA) is the most widely used serum biomarker to differentiate between malignant and benign prostate disease. Assays that measure PSA can be biased and/or nonequimolar and hence report significantly different PSA values for samples with the same nominal amount. This report investigates the effects of biased and nonequimolar assays on the decision to recommend a patient for a prostate biopsy based on age-specific PSA values.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research